Information Provided By: 
Fly News Breaks for January 6, 2017
NBIX
Jan 6, 2017 | 09:37 EDT
Leerink analyst Paul Matteis says that Neurocrine's valbenazine advisory committee meeting cancellation should be viewed "very positively." Furthermore, the analyst notes that he remains "positively biased" on the stock into a potential FDA approval, launch, and more near-term, Phase 2 data in Tourette's later in January. He reiterates an Outperform rating on the shares.
News For NBIX From the Last 2 Days
